cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.23949876
title: Additional file 6 of Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis

description: Additional file 6. Table S3. Component features in each module.
DOI: 10.6084/m9.figshare.23949876.v1
title: Additional file 6 of Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis

description: Additional file 6. Table S3. Component features in each module.
DOI: 10.6084/m9.figshare.23949879
title: Additional file 7 of Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis

description: Additional file 7. Table S4. Pathways associated with each module.
DOI: 10.6084/m9.figshare.23949879.v1
title: Additional file 7 of Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis

description: Additional file 7. Table S4. Pathways associated with each module.
DOI: 10.6084/m9.figshare.17134418
title: Pueraria flavones-loaded bile salt liposomes with improved intestinal absorption and oral bioavailability: <i>in vitro</i> and <i>in vivo</i> evaluation

description: Pueraria flavone (PF), the main component of <i>Pueraria lobata</i>, is a traditional Chinese medicine used for the treatment of cardiovascular and cerebrovascular diseases; however, it exhibits low oral bioavailability because of its poor membrane permeability. In this study, PF-loaded sodium deoxycholate-decorated liposomes (SDC-Lips) were prepared using the reverse-phase evaporation method and optimised using the Box–Behnken design method. The morphology, particle size, zeta potential, and entrapment efficiency of these PF-loaded SDC-Lips were evaluated. The release behaviours of PF-loaded SDC-Lips in simulated gastric and intestinal fluids were consistent with the Weibull kinetic model. <i>In situ</i> intestinal perfusion studies showed that the absorption characteristics of free PF in rats were mainly passive diffusion and partly active transport, and the duodenum was the main absorption site. After encapsulated with SDC-Lips, the absorption of PF increased significantly. The <i>in vivo</i> pharmacokinetic parameters of area under the plasma concentration–time curve (AUC)<sub>(0 → 12 h)</sub> and AUC<sub>(0 → ∞)</sub> of PF-loaded SDC-Lips after intragastric administration were 1.34-fold and 1.543-fold, respectively. Overall, the PF-loaded SDC-Lips improved the oral absorption of PF by increasing its solubility and might be considered a promising formulation strategy for prolonging the biological activity time of PF.
DOI: 10.6084/m9.figshare.10318706
title: Fibroblast growth factor 9 (FGF9) inhibits myogenic differentiation of C2C12 and human muscle cells

description: Osteoporosis and sarcopenia (osteosarcopenia (OS)) are twin-aging diseases. The biochemical crosstalk between muscle and bone seems to play a role in OS. We have previously shown that osteocytes produce soluble factors with beneficial effects on muscle and <i>vice versa</i>. Recently, enhanced FGF9 production was observed in the OmGFP66 osteogenic cell line. To test its role in myogenic differentiation, C2C12 myoblasts were treated with recombinant FGF9. FGF9 as low as 10 ng/mL inhibited myogenic differentiation, suggesting that FGF9 might be a potential inhibitory factor produced from bone cells with effects on muscle cells. FGF9 (10–50 ng/mL) significantly decreased mRNA expression of <i>MyoG</i> and <i>Mhc</i> while increasing the expression of <i>Myostatin</i>. Consistent with the phenotype, RT-qPCR array revealed that FGF9 (10 ng/mL) increased the expression of <i>Icam1</i> while decreased the expression of <i>Wnt1</i> and <i>Wnt6</i> decreased, respectively. FGF9 decreased caffeine-induced Ca<sup>2+</sup> release from the sarcoplasmic reticulum (SR) of C2C12 myotubes and reduced the expression of genes (i.e. <i>Cacna1s, RyR2, Naftc3</i>) directly associated with intracellular Ca<sup>2+</sup> homeostasis. Myogenic differentiation in human skeletal muscle cells was similarly inhibited by FGF9 but required higher doses of 200 ng/mL FGF9. FGF9 was also shown to stimulate C2C12 myoblast proliferation. FGF2 and the FGF9 subfamily members FGF16 and FGF20 also inhibited C2C12 myoblast differentiation and enhanced proliferation. Intriguingly, the differentiation inhibition was independent of proliferation enhancement. These findings suggest that FGF9 may modulate myogenesis via a complex signaling mechanism.
DOI: 10.6084/m9.figshare.10318706.v1
title: Fibroblast growth factor 9 (FGF9) inhibits myogenic differentiation of C2C12 and human muscle cells

description: Osteoporosis and sarcopenia (osteosarcopenia (OS)) are twin-aging diseases. The biochemical crosstalk between muscle and bone seems to play a role in OS. We have previously shown that osteocytes produce soluble factors with beneficial effects on muscle and <i>vice versa</i>. Recently, enhanced FGF9 production was observed in the OmGFP66 osteogenic cell line. To test its role in myogenic differentiation, C2C12 myoblasts were treated with recombinant FGF9. FGF9 as low as 10 ng/mL inhibited myogenic differentiation, suggesting that FGF9 might be a potential inhibitory factor produced from bone cells with effects on muscle cells. FGF9 (10–50 ng/mL) significantly decreased mRNA expression of <i>MyoG</i> and <i>Mhc</i> while increasing the expression of <i>Myostatin</i>. Consistent with the phenotype, RT-qPCR array revealed that FGF9 (10 ng/mL) increased the expression of <i>Icam1</i> while decreased the expression of <i>Wnt1</i> and <i>Wnt6</i> decreased, respectively. FGF9 decreased caffeine-induced Ca<sup>2+</sup> release from the sarcoplasmic reticulum (SR) of C2C12 myotubes and reduced the expression of genes (i.e. <i>Cacna1s, RyR2, Naftc3</i>) directly associated with intracellular Ca<sup>2+</sup> homeostasis. Myogenic differentiation in human skeletal muscle cells was similarly inhibited by FGF9 but required higher doses of 200 ng/mL FGF9. FGF9 was also shown to stimulate C2C12 myoblast proliferation. FGF2 and the FGF9 subfamily members FGF16 and FGF20 also inhibited C2C12 myoblast differentiation and enhanced proliferation. Intriguingly, the differentiation inhibition was independent of proliferation enhancement. These findings suggest that FGF9 may modulate myogenesis via a complex signaling mechanism.
DOI: 10.6084/m9.figshare.17133258.v1
title: Additional file 1 of Single-cell RNA-sequencing reveals the dynamic process and novel markers in porcine spermatogenesis

description: Additional file 1 supplementary Table1. List of data summary and the number of cells in each cluster.
DOI: 10.6084/m9.figshare.17133258
title: Additional file 1 of Single-cell RNA-sequencing reveals the dynamic process and novel markers in porcine spermatogenesis

description: Additional file 1 supplementary Table1. List of data summary and the number of cells in each cluster.
DOI: 10.6084/m9.figshare.7171856.v2
title: ESM 8 - FT-IR spectroscopy materials for LEC200 from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>.

description: Original datas for the FT-IR spectroscopy analysis
DOI: 10.6084/m9.figshare.7171859
title: ESM 10 - FT-IR spectroscopy materials for LEC400 from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>.

description: Original datas for the adsorption kinetics of biochars
DOI: 10.6084/m9.figshare.7171859.v1
title: ESM 10 - FT-IR spectroscopy materials for LEC400 from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>

description: Original datas for the adsorption kinetics of biochars
DOI: 10.6084/m9.figshare.7171874.v2
title: ESM 11 - FT-IR spectroscopy materials for LEC500 from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>.

description: Original datas for the thermodynamic studies
DOI: 10.6084/m9.figshare.7171877.v2
title: ESM 5 - Adsorption isotherms and thermodynamic studies from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>.

description: Original datas for the FT-IR spectroscopy analysis
DOI: 10.6084/m9.figshare.17133261
title: Additional file 2 of Single-cell RNA-sequencing reveals the dynamic process and novel markers in porcine spermatogenesis

description: Additional file 2 supplementary Table2. The expression of the genes involved in spermatogonia proliferation and differentiation in spermatogonia subsets
DOI: 10.6084/m9.figshare.7171859.v2
title: ESM 10 - FT-IR spectroscopy materials for LEC400 from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>.

description: Original datas for the adsorption kinetics of biochars
DOI: 10.6084/m9.figshare.7171868.v2
title: ESM 9 - FT-IR spectroscopy materials for LEC300 from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>.

description: Original datas for adsorbent dosage on metal adsorption
DOI: 10.6084/m9.figshare.7171871.v2
title: ESM 7 - Effect of contact time and initial metal concentration on adsorption kinetics from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>.

description: Original datas for the FT-IR spectroscopy analysis
DOI: 10.6084/m9.figshare.15036298.v1
title: The potential diagnostic value of extracellular vesicle miRNA for human non-small cell lung cancer: a systematic review and meta-analysis

description: <b>Background</b>: This meta-analysis aimed to evaluate the diagnostic accuracy of extracellular vesicles (EV) miRNAs for non‐small cell lung cancer (NSCLC).<b>Methods</b>: All eligible studies were searched in an online database. Stata 15.0, Meta-disc 14.0 and Review Manager 5.2 software packages were used to perform all statistical analysis.<b>Results</b>: The analysis included 16 articles and 70 studies. Pooled sensitivity (SEN) and specificity (SPE), positive predictive value and negative predictive value were 0.77 (95% CI: 0.72–0.80), 0.83 (95% CI: 0.78–0.86), 0.88 (95% CI: 0.86–0.90) and 0.63 (95% CI: 0.58–0.68), respectively. The overall diagnostic odds ratio (DOR) was 16 (95% CI: 11–21) and the area under the curve (AUC) was 0.86 (95% CI: 0.83–0.89). 3 EV miRNAs could identify metastatic NSCLC from healthy, and 10 distinguish early-stage NSCLC. The respective targets of EV miR-21, miR-210, and miR-1290 could activate PI3K/AKT-related pathway.<b>Conclusion</b>: EV miRNAs had high diagnostic accuracy (AUC = 0.86) for NSCLC, especially metastatic NSCLC (AUC = 0.90), and early-stage NSCLC (AUC = 0.88). Besides, multitudinous EV miRNAs combined showed higher diagnostic value than alone. EV miR-21, miR-210, and miR-1290 might be associated with PI3K/AKT-related pathway and the valuable diagnostic biomarkers for NSCLC.
DOI: 10.6084/m9.figshare.17134636
title: Identification and in vitro validation of prognostic lncRNA signature in head and neck squamous cell carcinoma

description: Long non-coding RNAs (lncRNAs) are promising cancer prognostic markers. However, the clinical significance of lncRNA signatures in evaluating overall survival (OS) outcomes of head and neck squamous cell carcinoma (HNSCC) has not been explored. This study aimed to assess the significance of lncRNA in HNSCC and to develop a lncRNA signature related to OS in HNSCC. LncRNA expression matrices were retrieved from the Cancer Genome Atlas (TCGA) data. Least Absolute Shrinkage and Selection of the Operator (LASSO), univariate and multivariate Cox regression were used for establishing a prognostic model. In vitro experiments were carried out to demonstrate the biological role of lncRNA. A prognosis model based on 7 DElncRNAs was finally established.The patients were then divided into high-risk and low-risk groups. Relative to the low-risk group, overall survival times for patients in the high-risk group were significantly low (P=2.466e−07). Risk score remained an independent prognostic factor in univariate (HR=1.329, 95%CI=1.239−1.425, p &lt; 0.001) and multivariate (HR=1.279, 95%CI=1.184−1.382, p &lt; 0.001) Cox regression analyses. The area under the curve (AUC) of the signature was as high as 0.78. Expressions of FOXD2-AS1  in tumor tissues were elevated, and significantly correlated with OS (P=0.008). FOXD2-AS1 silencing then significantly reduced HNSCC cell proliferation, invasion, and migration. In conclusion, a lncRNA signature was established for HNSCC prognostic prediction and FOXD2-AS1 was identified as an HNSCC oncogene.
DOI: 10.6084/m9.figshare.17134637
title: Hsa_circ_0001879 promotes the progression of atherosclerosis by regulating the proliferation and migration of oxidation of low density lipoprotein (ox-LDL)-induced vascular endothelial cells via the miR-6873-5p-HDAC9 axis

description: Atherosclerosis (AS) is a typical vascular disease. Emerging evidence has shown that circRNAs play key roles in the progression of AS, but the potential function and underlying mechanism of hsa_circ_0001879 remains unknown. We detected the expression level of hsa_circ_0001879 was determined by qRT-PCR, and the proliferation rate and migration ability of HUVECs were measured by CCK-8 assay and Transwell assay, respectively. Proliferative markers and epithelium mesenchymal transition (EMT) markers were measured through immunoblotting. A dual luciferase activity assay was performed to detect the interaction between circRNAs, miRNAs, and mRNAs. Hsa_circ_0001879 was upregulated in AS patients. Hsa_circ_0001879 inhibited the proliferation and migration ability of Human umbilical vein endothelial cells (HUVECs). Hsa_circ_0001879 directly bound to miR-6873-5p and acted as a sponge. miR-6873-5p-induced HDAC9 mRNA degradation was inhibited by hsa_circ_0001879. Hsa_circ_0001879 decreased the proliferation and migration of HUVECs by inhibiting miR-6873-5p-induced HDAC9 degradation.
DOI: 10.6084/m9.figshare.17134642
title: <i>Polygonatum sibiricum</i> polysaccharides (PSP) improve the palmitic acid (PA)-induced inhibition of survival, inflammation, and glucose uptake in skeletal muscle cells

description: <i>Polygonatum sibiricum</i> polysaccharides (PSP) can decrease the levels of fasting blood glucose, total cholesterol, and triglyceride (TG) in hyperlipidemic and diabetic animals. It can also reduce inflammatory cytokines and promote glucose uptake in adipocytes. However, the underlying molecular mechanisms of PSP in improving insulin resistance (IR) in skeletal muscle remain unclear. In this study, palmitic acid (PA) induced an IR model in L6 myotubes. After treatment, cell proliferation was measured using the CCK8. miR-340-3p, glucose transporter 4 (GLUT-4), and interleukin-1 receptor-associated kinase 3 (IRAK3) expression was measured by qRT-PCR. IRAK3 protein levels were measured by Western blotting. Glucose in the cell supernatant, TG concentration in L6 myotubes, and the levels of IL-1β, IL-6, and TNF-α were measured by an ELISA. We found that cell survival, glucose uptake, and GLUT-4 expression in L6 myotubes were significantly suppressed, while lipid accumulation and inflammatory factor levels were enhanced by PA stimulation. Furthermore, PSP treatment markedly alleviated these effects. Interestingly, PSP also significantly reduced the upregulated expression of miR-340-3p in the L6 myotube model of IR. Furthermore, overexpression of miR-340-3p reversed the beneficial effects of PSP in the same IR model. miR-340-3p can bind to the 3′-untranslated regions of <i>IRAK3</i>. Additionally, PA treatment inhibited IRAK3 expression, whereas PSP treatment enhanced IRAK3 expression in L6 myotubes. Additionally, miR-340-3p also inhibited IRAK3 expression in L6 myotubes. Taken together, PSP improved inflammation and glucose uptake in PA-treated L6 myotubes by regulating miR-340-3p/IRAK3, suggesting that PSP may be suitable as a novel therapeutic agent for IR.
DOI: 10.6084/m9.figshare.24998973
title: Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study

description: Iruplinalkib is a novel anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive crizotinib-resistant NSCLC. A single oral dose of 120 mg/3.7 MBq [<sup>14</sup>C]iruplinalkib was administered to healthy subjects. Blood, urine and fecal samples were collected and analyzed for iruplinalkib and its metabolites. The safety of iruplinalkib was also assessed. Iruplinalkib was absorbed quickly and eliminated slowly from plasma, with a T<sub>max</sub> of 1.5 h and t<sub>1/2</sub> of 28.6 h. About 88.85% of iruplinalkib was excreted at 312 h, including 20.23% in urine and 68.63% in feces. Seventeen metabolites of iruplinalkib were identified, and M3b (demethylation), M7 (cysteine conjugation), M11 (oxidative dehydrogenation and cysteine conjugation of M3b) and M12 (oxidative dehydrogenation and cysteine conjugation) were considered the prominent metabolites in humans. Iruplinalkib-related compounds were found to be covalently bound to proteins, accounting for 7.70% in plasma and 17.96% in feces, which suggested chemically reactive metabolites were formed. There were no serious adverse events observed in the study. Iruplinalkib was widely metabolized and excreted mainly through feces in humans. Unchanged iruplinalkib, cysteine conjugates and covalent protein binding products were the main drug-related compounds in circulation. Iruplinalkib was well tolerated at the study dose. The trial is registered at ClinicalTrials.gov (Identifier: Anonymized).
DOI: 10.6084/m9.figshare.24998973.v2
title: Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study

description: Iruplinalkib is a novel anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive crizotinib-resistant NSCLC. A single oral dose of 120 mg/3.7 MBq [<sup>14</sup>C]iruplinalkib was administered to healthy subjects. Blood, urine and fecal samples were collected and analyzed for iruplinalkib and its metabolites. The safety of iruplinalkib was also assessed. Iruplinalkib was absorbed quickly and eliminated slowly from plasma, with a T<sub>max</sub> of 1.5 h and t<sub>1/2</sub> of 28.6 h. About 88.85% of iruplinalkib was excreted at 312 h, including 20.23% in urine and 68.63% in feces. Seventeen metabolites of iruplinalkib were identified, and M3b (demethylation), M7 (cysteine conjugation), M11 (oxidative dehydrogenation and cysteine conjugation of M3b) and M12 (oxidative dehydrogenation and cysteine conjugation) were considered the prominent metabolites in humans. Iruplinalkib-related compounds were found to be covalently bound to proteins, accounting for 7.70% in plasma and 17.96% in feces, which suggested chemically reactive metabolites were formed. There were no serious adverse events observed in the study. Iruplinalkib was widely metabolized and excreted mainly through feces in humans. Unchanged iruplinalkib, cysteine conjugates and covalent protein binding products were the main drug-related compounds in circulation. Iruplinalkib was well tolerated at the study dose. The trial is registered at ClinicalTrials.gov (Identifier: Anonymized).
DOI: 10.6084/m9.figshare.16610486
title: Lychee seed polyphenol protects blood–retinal barrier by increasing tight joint proteins and inhibiting the activation of TLR4/MYD88/NF-κB-mediated NLRP3 inflammasome

description: Emerging evidence indicates that blood–retinal barrier (BRB) damage is the main cause of diabetic retinopathy (DR), and the downregulation of tight proteins (TJs) located between endothelial cells and the activation of NLRP3 inflammasome-mediated inflammation in Müller cells result in BRB injury. In this study, we aimed to study the protective effect of lychee seed polyphenol (LSP) on BRB integrity and the mechanism of action. By establishing a cellular model of BRB injury by using high glucose (HG)-induced hRECs or co-culture system of hRECs with MIO-M1 cells, we found that LSP significantly maintained the integrity of monolayer of hRECs as revealed by the decreased PD40 permeability and increased TJs, including ZO-1, Occludin, and Claudin 5. In addition, LSP inhibited the NLRP3 inflammasome activation and the levels of inflammatory cytokines via the TLR4/MYD88/NF-κB pathway. Collectively, this study provides valuable insight into the utilization of LSP in the treatment of DR.
DOI: 10.6084/m9.figshare.25245730
title: treefile in the Fig. 5b

description: treefile in the Fig. 5bBacteria: Fig.5b_bac.treefileArchaea: Fig.5b_ar.treefile
DOI: 10.6084/m9.figshare.23950584
title: BioNet_Data

description: Texture features and corresponding locations of all samples inside big ROI on cohort A and cohort B. Raw scores of three gene modules and corresponding locations of all biopsies on cohort A and cohort B.
DOI: 10.6084/m9.figshare.7171874
title: ESM 11 - FT-IR spectroscopy materials for LEC500 from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>.

description: Original datas for the thermodynamic studies
DOI: 10.5281/zenodo.10680616
title: ТАФСИР ИЛМИГА ОИД НОЁБ МАНБА
DOI: 10.5281/zenodo.10680617
title: ТАФСИР ИЛМИГА ОИД НОЁБ МАНБА
DOI: 10.6084/m9.figshare.7171871
title: ESM 7 - Effect of contact time and initial metal concentration on adsorption kinetics from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>.

description: Original datas for the FT-IR spectroscopy analysis
DOI: 10.6084/m9.figshare.7171874.v1
title: ESM 11 - FT-IR spectroscopy materials for LEC500 from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>

description: Original datas for the thermodynamic studies
DOI: 10.6084/m9.figshare.7171865
title: ESM 6 - Effect of adsorbent dosage on adsorption from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>.

description: Original datas for the FT-IR spectroscopy analysis
DOI: 10.6084/m9.figshare.7171865.v1
title: ESM 6 - Effect of adsorbent dosage on adsorption from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>

description: Original datas for the FT-IR spectroscopy analysis
DOI: 10.6084/m9.figshare.7171868
title: ESM 9 - FT-IR spectroscopy materials for LEC300 from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>.

description: Original datas for adsorbent dosage on metal adsorption
DOI: 10.6084/m9.figshare.7171868.v1
title: ESM 9 - FT-IR spectroscopy materials for LEC300 from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>

description: Original datas for adsorbent dosage on metal adsorption
DOI: 10.6084/m9.figshare.7171877.v1
title: ESM 5 - Adsorption isotherms and thermodynamic studies from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>

description: Original datas for the FT-IR spectroscopy analysis
DOI: 10.6084/m9.figshare.7171856.v1
title: ESM 8 - FT-IR spectroscopy materials for LEC200 from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>

description: Original datas for the FT-IR spectroscopy analysis
DOI: 10.6084/m9.figshare.7171871.v1
title: ESM 7 - Effect of contact time and initial metal concentration on adsorption kinetics from Removal of toxic metals from aqueous solution by biochars derived from long-root <i>Eichhornia crassipes</i>

description: Original datas for the FT-IR spectroscopy analysis
DOI: 10.6084/m9.figshare.17135072
title: Athlete Sub301

description: EEG and ET mat format data of one Archery Athlete Sub301 in ABT and CCT experiments.